Milan Bogojevic

Dr. Milan Bogojevic

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2023 in Medicina
Verified
Journal Article
Open access
PDF file
SPSlavica Pavlov-Dolijanovic
Slavica Pavlov-Dolijanovic
MBMilan Bogojevic
Milan Bogojevic
TRTatjana Nozica Radulovic
Tatjana Nozica Radulovic
Goran RadunovicGoran Radunovic
Goran Radunovic
NMNatasa Mujovic
Natasa Mujovic
Elderly-onset rheumatoid arthritis (EORA) is a distinct clinical entity defined as the onset of rheumatoid arthritis (RA) in individuals aged over 60 years. EORA presents unique clinical features, including a more equitable distribution of sexes, a potential predilection for male involvement, a higher incidence of acute onset characterized by constitutional symptoms, a propensity for systemic manifestations, elevated sedimentation rates at disease onset, a reduced occurrence of rheumatoid factor positivity, increased titers of anti-citrullinated protein antibodies, a preference for involvement of large joints, elevated disease activity, the presence of bone erosions, and heightened patient disability. RA is recognized to consist of three partially overlapping subsets. One subset mirrors the classical RA clinical presentation, while the remaining subsets exhibit either a polymyalgia rheumatica-like phenotype or present with remitting seronegative symmetrical synovitis accompanied by pitting edema syndrome. In the initial stages of EORA management, non-steroidal anti-inflammatory drugs (NSAIDs) are not typically the first-line treatment choice, because seniors are much more prone to develop side effects due to NSAIDs, and the use of NSAIDs is in reality contraindicated to the majority of seniors due to comorbidities. Disease-modifying antirheumatic drugs (DMARDs), frequently methotrexate, are introduced immediately after the diagnosis is made. In cases where elderly patients demonstrate resistance to conventional DMARD therapy, the introduction of biological or targeted synthetic DMARDs becomes a viable treatment option. EORA presents a unique clinical profile, necessitating tailored treatment strategies. Our study emphasizes the challenges of NSAID use in seniors, highlighting the imperative shift toward DMARDs such as methotrexate. Future research should explore personalized DMARD approaches based on disease activity, comorbidities, and safety considerations, aiming to optimize treatment outcomes and minimize glucocorticoid reliance, thereby enhancing the quality of care for EORA patients.

19 September 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MBMilan Bogojevic
Milan Bogojevic
MMMilica Markovic
Milica Markovic
RMRifat Medjedovic
Rifat Medjedovic
ESElvira Strujic
Elvira Strujic
DLDragana Pravilovic Lutovac
Dragana Pravilovic Lutovac
SPSlavica Pavlov-Dolijanovic
Slavica Pavlov-Dolijanovic
Background/Objectives: Idiopathic inflammatory myopathies (IIMs) are rare autoimmune disorders characterized by progressive proximal muscle weakness and varying extra-muscular manifestations. The latest 2017 EULAR/ACR criteria classify them into subgroups. This study aims to evaluate the role of nailfold capillaroscopy (NFC) as a diagnostic and prognostic tool in IIMs by comparing capillaroscopic patterns across different IIM subtypes. Methods: We conducted an observational, cross-sectional study at the Institute of Rheumatology in Belgrade, analyzing 90 patients diagnosed with IIMs per the 2017 EULAR/ACR criteria. Patients were categorized into dermatomyositis (DM) (n = 37), polymyositis (PM) (n = 35), amyopathic dermatomyositis (ADM) (n = 13), and juvenile dermatomyositis (JDM) (n = 5). A control group of 35 patients with primary Raynaud’s phenomenon was also included. NFC findings, clinical manifestations, and laboratory data were compared across the groups. Results: In DM, 81.9% exhibited a scleroderma capillaroscopic pattern, which was also present in 76.9% of ADM patients. In PM, the most common pattern was nonspecific changes (48.6%). JDM patients showed a high prevalence of scleroderma changes (n = 4 (80%)). Scleroderma patterns correlated with Gottron’s papules, heliotrope rash, periungual erythema, Raynaud’s phenomenon, and interstitial lung disease (ILD). No significant differences were found in laboratory parameters across capillaroscopic groups, except for a higher prevalence of anti-Jo1 antibodies in patients with nonspecific capillaroscopic changes. Conclusions: NFC is a valuable tool for differentiating IIM subtypes and correlating clinical manifestations with specific capillaroscopic patterns. The high prevalence of scleroderma changes in DM and ADM suggests their potential as a diagnostic and prognostic marker in IIMs. Further research with larger cohorts is warranted to validate these findings.

Verified
Journal Article
Open access
PDF file
SPSlavica Pavlov-Dolijanovic
Slavica Pavlov-Dolijanovic
IJIvan Jeremic
Ivan Jeremic
MBMilan Bogojevic
Milan Bogojevic
ZVZoran Mile Veličković
Zoran Mile Veličković
MZMirjana Zlatkovic-Svenda
Mirjana Zlatkovic-Svenda
Goran RadunovicGoran Radunovic
Goran Radunovic
Background: The European League Against Rheumatism (EULAR), in collaboration with the European Scleroderma Trial and Research group (EUSTAR), published the first set of treatment recommendations for systemic sclerosis (SSc) in 2009, with subsequent updates in 2016 and 2023. Objectives: This study aimed to evaluate how rheumatologists’ clinical approaches to the treatment of SSc evolved following the 2016 update of the clinical management guidelines. Methods: Medication use for SSc was analyzed in a cohort of 378 patients. The patients were stratified based on enrollment before (233 patients) and after (145 patients) the guideline update, and medication usage was compared between the two groups. Results: Although all patients presented with Raynaud’s phenomenon (RP), only 35% received calcium channel blockers. Medications such as iloprost, phosphodiesterase type 5 (PDE-5) inhibitors, fluoxetine, and bosentan, recommended for the treatment of RP and digital ulcers, were not approved for SSc by the Republic Health Insurance Fund. Treatment for pulmonary arterial hypertension (PAH) was administered to only 16 patients (4.2%), including 2 who received bosentan, 10 who received PDE-5 inhibitors, and 4 who were treated with riociguat. The use of PDE-5 inhibitors increased following the 2016 update of the guidelines. Cyclophosphamide was consistently prescribed for interstitial lung disease (ILD), with an increased frequency observed after the guideline update. No significant differences were observed in the use of methotrexate for skin involvement, ACE inhibitors for scleroderma renal crisis, or antibiotics for gastrointestinal symptoms. Proton pump inhibitors (PPIs) were prescribed to 87.3% of patients with gastrointestinal involvement, with an increase in use of both PPIs and prokinetic agents following the guideline update. Conclusions: Rheumatologists’ adherence to the EULAR/EUSTAR guidelines varied considerably, with 25% to 100% of eligible patients receiving the recommended treatments. Concordance improved in the management of PAH, ILD, and gastrointestinal involvement after the 2016 guideline update.

7 October 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
RMRifat Medjedovic
Rifat Medjedovic
MBMilan Bogojevic
Milan Bogojevic
MMMilica Markovic
Milica Markovic
ISIvan Soldatovic
Ivan Soldatovic
Background/Objectives: Systemic lupus erythematosus (SLE) is an autoimmune disease affecting multiple organ systems, characterized by remissions and relapses. Musculoskeletal involvement occurs in up to 95% of patients and may present as the initial symptom in 50%. Such involvement is often subclinical, without obvious joint or tendon inflammation. Musculoskeletal ultrasound (US) has proven valuable for detecting pathological changes in joints and periarticular structures, including in SLE patients, and early detection, particularly in subclinical stages, supports optimal therapy, monitoring, and improved prognosis. This study aimed to determine the frequency of new clinical manifestations in patients with previously confirmed clinical and subclinical musculoskeletal inflammation after 2 and 5 years, and to evaluate associations with sex, age, BMI, smoking status, ESR, CRP, SLEDAI-2K, complement components C3 and C4, anti-dsDNA antibodies concentrations, and prior treatment. Methods: The study included 34 SLE patients with clinical and 22 with subclinical musculoskeletal inflammation, confirmed at baseline by history, examination, and US. Follow-up at 2 and 5 years recorded new clinical manifestations. Correlations with patient characteristics were assessed to identify predictors. Results: New clinical manifestations occurred in 34% of patients at 2 years and 48% at 5 years, most commonly cutaneous, musculoskeletal, and hematological. Summary analysis identified female sex, lower BMI, and lower baseline SLEDAI-2K scores as the strongest predictors. In the subclinical group, female sex, smoking, and lower SLEDAI-2K scores were predictive, while in the clinical group, female sex, lower SLEDAI-2K scores, lower ESR, and higher anti-ds DNA levels were associated with new manifestations. Conclusions: Female sex, lower BMI, and lower baseline SLEDAI-2K scores are key predictors of new clinical manifestations in SLE patients, highlighting the importance of early detection and individualized monitoring, particularly in patients with subclinical musculoskeletal inflammation.

1 January 2025 in Medicinska istrazivanja
Verified
Journal Article
Open access
PDF file
SPSlavica Pavlov-Dolijanovic
Slavica Pavlov-Dolijanovic
MBMilan Bogojevic
Milan Bogojevic
DPDragana Pravilović-Lutovac
Dragana Pravilović-Lutovac
MZMirjana Zlatkovic-Svenda
Mirjana Zlatkovic-Svenda
AMAna Markovic
Ana Markovic
Goran RadunovicGoran Radunovic
Goran Radunovic
Introduction: Capillaroscopy is a non-invasive diagnostic tool used to detect morphological abnormalities in the microcirculation. The assessment of capillaroscopic findings in healthy subjects is likely the area where controversies are most difficult to resolve. This review focuses on capillary architecture in healthy individuals across different age groups. Methods: A search was conducted in PubMed, MEDLINE, and Scopus using the following terms: capillaroscopy, healthy subjects, Raynaud's phenomenon, microcirculation, and microvascular abnormalities. A total of 10 relevant articles were identified. Results: The shape of capillaries and the architecture of the nailfold microvascular network can vary significantly among healthy individuals. The most commonly observed abnormalities in this population include tortuosity, crossovers, homogeneously enlarged loops, neoangiogenic capillaries, and microbleeding. Less frequently, more unusual patterns, such as ramified, bushy, or glomerular loops may be observed. These atypical features require careful evaluation to avoid missing a potential underlying disease. Conclusion: This review critically examines capillaroscopy findings in healthy individuals, taking into account typical nail care practices and age-related changes. These insights may assist clinicians in distinguishing physiological variations from early signs of microvascular damage.

2 January 2026 in Clinical Case Reports
Verified
Journal Article
Open access
MBMilan Bogojevic
Milan Bogojevic
RMRifat Medjedovic
Rifat Medjedovic
MMMilica Markovic
Milica Markovic
NBNikola Bakic
Nikola Bakic
DLDragana Pravilovic Lutovac
Dragana Pravilovic Lutovac
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by synovial inflammation and joint destruction, whereas polycythemia vera (PV) is a myeloproliferative neoplasm driven by the Janus kinase (JAK)2 V617F mutation, resulting in erythrocytosis and increased thromboembolic risk. Although JAK inhibitors are established in rheumatology, most selectively inhibit JAK1 and JAK3, sparing JAK2 activity, which is central to PV pathogenesis. We describe a 61‐year‐old woman with seropositive RA and JAK2 V617F‐positive PV. Treatment for polycythemia vera included hydroxyurea. Methotrexate and sulfasalazine were prescribed for rheumatoid arthritis but were withdrawn due to intolerance, and therapy was switched to tofacitinib 5 mg twice daily. Within 3 months, she achieved clinical and ultrasonographic remission of RA, with improvement of inflammatory markers. Hematologic parameters remained stable throughout follow‐up. After 6 months, a mild improvement allowed reduction in hydroxyurea dosing, although further tapering resulted in recurrence of erythrocytosis. After 12 months of therapy, RA remission persisted without adverse events or cytopenias. Tofacitinib demonstrated rheumatologic efficacy but minimal effect on PV‐related hematologic activity.